港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

映恩生物-B

207.400

-7.000-3.26%

成交量：23.77萬

成交額：4,990.51萬

市值：177.20億

市盈率：-1.48

高：218.800

開：216.000

低：206.800

收：214.400

資料載入中...

總覽公司新聞公告

映恩生物-B04月30日主力淨流出148.3萬元散户資金買入

異動解讀 | 映恩生物-B盤中大漲5.01%，兩項研究將在美國臨牀腫瘤學會年會公佈

港股異動 | 映恩生物-B(09606)尾盤漲超4% 兩項研究結果將在2025美國臨牀腫瘤學會年會公佈

映恩生物-B04月25日遭主力拋售578萬元

【熱門行業】全球競逐加速中國創新藥行業進入新週期

映恩生物兩項研究結果將在2025美國臨牀腫瘤學會年會公佈

醫藥生物週報：映恩生物完成港股IPO 繼續推薦關注具備全球潛力的創新藥標的

国信证券股份有...

映恩生物-B04月22日主力淨流入272萬元散戶資金拋售

映恩生物-B午後漲超15% 國泰海通給予“增持”評級

異動解讀 | 映恩生物-B盤中大漲15%，ADC新藥研發引發市場熱捧

異動解讀 | 映恩生物-B盤中大漲15%，ADC新藥研發進展及券商看好推動股價創新高

港股異動 | 映恩生物-B(09606)漲超16%創新高公司聚焦ADC新藥研發核心產品初步展現治療潛力

智通财经网

國泰海通：首予映恩生物-B(09606)“增持”評級目標價300.70港元

港股IPO週報：映恩生物-B首日暴漲116.7%，“最賺錢”卡牌龍頭卡遊等9家遞表

映恩生物上市暴漲116%，未來價值釋放值得期待

創下2022年以來18A融資規模新紀錄，ADC獨角獸映恩生物-B(09606)強勢登陸港股

智通财经网

映恩生物－Ｂ(09606)股價下跌5.366%，現價港幣$194.0

阿斯达克财经

映恩生物登陸港交所首日大漲116.70%；百利天恆第10款ADC獲批臨牀試驗 | 醫藥早參

每日经济新闻

映恩生物上市刷新港股18A多項紀錄首日股價飆升超116%

映恩生物港股上市首日收漲116.7%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/09606/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":207.4,"timestamp":1746000497038,"preClose":214.4,"halted":0,"volume":237685,"delay":0,"floatShares":85436500,"shares":85436464,"eps":-139.96286004312955,"marketStatus":"未開盤","change":-7,"latestTime":"04-30 16:08:17","open":216,"high":218.8,"low":206.8,"amount":49905064,"amplitude":0.05597,"askPrice":207.4,"askSize":200,"bidPrice":207,"bidSize":600,"shortable":0,"etf":0,"ttmEps":-139.96287070256142,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1746149400000},"marketStatusCode":0,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":214.4,"openAndCloseTimeList":[[1745976600000,1745985600000],[1745989200000,1746000000000]],"volumeRatio":0.3775980768748601,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","floatShares":85436500,"roa":"-6.51%","roe":"--","lyrEps":-139.964225,"volumeRatio":0.3775980768748601,"shares":85436464,"dividePrice":0,"high":218.8,"amplitude":0.05597,"preClose":214.4,"low":206.8,"week52Low":178.8,"pbRate":"-8.20","psRate":"8.56","week52High":234.6,"institutionHeld":0,"latestPrice":207.4,"committee":0.5,"eps":-139.96421446632897,"divideRate":0,"volume":237685,"delay":0,"ttmEps":-139.964225125864,"open":216,"prevYearClose":94.6,"prevWeekClose":207.4,"prevMonthClose":207.4,"prevQuarterClose":94.6,"fiveDayClose":218.6,"twentyDayClose":94.6,"sixtyDayClose":94.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09606\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531089001","title":"映恩生物-B04月30日主力淨流出148.3萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2531089001","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531089001?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 16:15","pubTimestamp":1746000936,"startTime":"0","endTime":"0","summary":"04月30日, 映恩生物-B股价跌3.26%，报收207.40元，成交金额4990.5万元，换手率0.28%，振幅5.60%，量比0.38。映恩生物-B今日主力资金净流出148.3万元，上一交易日主力净流入885.1万元。该股近5个交易日下跌5.49%，主力资金累计净流入569.7万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出504.4万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170901a46d74ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170901a46d74ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606"],"gpt_icon":0},{"id":"1124349230","title":"異動解讀 | 映恩生物-B盤中大漲5.01%，兩項研究將在美國臨牀腫瘤學會年會公佈","url":"https://stock-news.laohu8.com/highlight/detail?id=1124349230","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124349230?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 15:56","pubTimestamp":1745826981,"startTime":"0","endTime":"0","summary":"映恩生物-B今日盘中大涨5.01%，引发市场关注。截至发稿时，该股报216.6港元，成交额达1.49亿港元。消息面上，公司将在即将举行的2025年美国临床肿瘤学会年会上公布两项重要研究结果。ASCO年会将于5月30日至6月3日在美国芝加哥举行，相关研究摘要全文将于5月23日在ASCO官方网站发布。此外，国泰海通发布的最新研报也为映恩生物-B带来利好。这些积极因素共同推动了映恩生物-B股价的上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09606"],"gpt_icon":0},{"id":"2530442210","title":"港股異動 | 映恩生物-B(09606)尾盤漲超4% 兩項研究結果將在2025美國臨牀腫瘤學會年會公佈","url":"https://stock-news.laohu8.com/highlight/detail?id=2530442210","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530442210?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 15:49","pubTimestamp":1745826580,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B尾盘涨超4%，截至发稿，涨4.44%，报216.6港元，成交额1.49亿港元。消息面上，2025年美国临床肿瘤学会年会将于5月30日至6月3日在美国芝加哥举行。映恩生物将在以口头报告形式公布HER3 ADC DB-1310及B7H3 ADC DB-1311/BNT324的两项研究结果，相关研究摘要全文将于当地时间2025年5月23日发布在 ASCO 官方网站上。国泰海通发布研报称，公司聚焦ADC新药研发，产品达成多项License-out对外授权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 映恩生物-B(09606)尾盘涨超4% 两项研究结果将在2025美国临床肿瘤学会年会公布","news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09606"],"gpt_icon":0},{"id":"2530909349","title":"映恩生物-B04月25日遭主力拋售578萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530909349","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530909349?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 16:17","pubTimestamp":1745569048,"startTime":"0","endTime":"0","summary":"04月25日, 映恩生物-B股价跌7.82%，报收207.40元，成交金额1.58亿元，换手率0.85%，振幅10.49%，量比0.63。映恩生物-B今日主力资金净流出578万元，连续3日净流出，上一交易日主力净流出67万元。该股近5个交易日上涨9.29%，主力资金累计净流出1470万元；近20日主力资金累计净流出1719万元，其中净流出天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425171123a46694b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425171123a46694b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606"],"gpt_icon":1},{"id":"2529349605","title":"【熱門行業】全球競逐加速 中國創新藥行業進入新週期","url":"https://stock-news.laohu8.com/highlight/detail?id=2529349605","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529349605?lang=zh_tw&edition=fundamental","pubTime":"2025-04-24 18:06","pubTimestamp":1745489202,"startTime":"0","endTime":"0","summary":"这一举措直接惠及映恩生物等创新药企。特朗普政府宣布对药品加征关税后，市场担忧依赖美国市场的企业将承压。美国作为全球最大采浆国，其人血白蛋白长期占据中国市场主导地位；高端医疗器械领域亦以进口产品为主。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/NzE2MmQxNjEyNzIzMzUyNjY5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NzE2MmQxNjEyNzIzMzUyNjY5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1957660","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU0417516571.SGD","LU0348784397.USD","02696","LU2488822045.USD","BK1574","159992","06978","LU1720050803.USD","IE00B543WZ88.USD","09926","LU1794554557.SGD","09606","LU0348783233.USD","IE00B5MMRT66.SGD","BK1161"],"gpt_icon":1},{"id":"2529269846","title":"映恩生物兩項研究結果將在2025美國臨牀腫瘤學會年會公佈","url":"https://stock-news.laohu8.com/highlight/detail?id=2529269846","media":"氨基观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529269846?lang=zh_tw&edition=fundamental","pubTime":"2025-04-24 14:41","pubTimestamp":1745476868,"startTime":"0","endTime":"0","summary":"2025年美国临床肿瘤学会年会将于5月30日至6月3日在美国芝加哥举行。映恩生物将在以口头报告形式公布HER3 ADC DB-1310及B7H3 ADC DB-1311/BNT324的两项研究结果，相关研究摘要全文将于当地时间 2025年5月23日发布在 ASCO 官方网站上。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424145928a464ecd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424145928a464ecd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606"],"gpt_icon":1},{"id":"2529610434","title":"醫藥生物週報：映恩生物完成港股IPO 繼續推薦關注具備全球潛力的創新藥標的","url":"https://stock-news.laohu8.com/highlight/detail?id=2529610434","media":"国信证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529610434?lang=zh_tw&edition=fundamental","pubTime":"2025-04-24 00:00","pubTimestamp":1745424000,"startTime":"0","endTime":"0","summary":"映恩生物完成港股IPO。映恩生物成立于2019 年7 月，为ADC 领域的全球领先企业，致力于研发针对癌症和自身免疫性疾病的新一代ADC 创新药。其中，7 款临床阶段的ADC候选药物，在多个适应症中具备治疗潜力，2 款新一代特异性ADC 药物预计2025-2026 年进入临床阶段，以及开发多款其他临床前ADC 药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504241129309742fb49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504241129309742fb49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HSTECH","06978","09606","BK1574"],"gpt_icon":1},{"id":"2529532107","title":"映恩生物-B04月22日主力淨流入272萬元 散戶資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529532107","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529532107?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 16:15","pubTimestamp":1745309744,"startTime":"0","endTime":"0","summary":"04月22日, 映恩生物-B股价涨9.80%，报收219.60元，成交金额2.91亿元，换手率1.54%，振幅14.50%，量比0.00。映恩生物-B今日主力资金净流入272万元，上一交易日主力净流出591万元。该股近5个交易日上涨131.71%，主力资金累计净流出568万元；近20日主力资金累计净流出568万元，其中净流出天数为2日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422170825a6c38aad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422170825a6c38aad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606"],"gpt_icon":0},{"id":"2529315118","title":"映恩生物-B午後漲超15% 國泰海通給予“增持”評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2529315118","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529315118?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 13:22","pubTimestamp":1745299320,"startTime":"0","endTime":"0","summary":"　　映恩生物-B早盘涨超16%，高见234港元，创上市新高。午后上涨15.20%，现报230.80港元，成交额1.97亿港元。　　公开资料显示，映恩生物是全球抗体偶联药物领域的关键领跑者，致力于为癌症和自身免疫性疾病等患者研发ADC创新药物。　　国泰海通发布研报称，公司聚焦ADC新药研发，产品达成多项License-out对外授权。首次覆盖，给予“增持”评级。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-22/doc-inetzkuy0978708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09606"],"gpt_icon":1},{"id":"1118159098","title":"異動解讀 | 映恩生物-B盤中大漲15%，ADC新藥研發引發市場熱捧","url":"https://stock-news.laohu8.com/highlight/detail?id=1118159098","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118159098?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 12:46","pubTimestamp":1745297189,"startTime":"0","endTime":"0","summary":"映恩生物-B今日盘中大涨15.00%，股价一度触及232.8港元的历史新高，引发市场广泛关注。截至盘中，该股报226.4港元，成交额达1.75亿港元。映恩生物是全球抗体偶联药物领域的关键领跑者，专注于为癌症和自身免疫性疾病等患者研发ADC创新药物。国泰海通发布的最新研报进一步推动了映恩生物-B的股价上涨。该券商看好公司聚焦ADC新药研发的战略，以及产品达成的多项对外授权。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09606"],"gpt_icon":0},{"id":"1194208776","title":"異動解讀 | 映恩生物-B盤中大漲15%，ADC新藥研發進展及券商看好推動股價創新高","url":"https://stock-news.laohu8.com/highlight/detail?id=1194208776","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194208776?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 12:46","pubTimestamp":1745297189,"startTime":"0","endTime":"0","summary":"映恩生物-B今日盘中大涨15%，股价一度触及232.8港元，创上市以来新高。截至11时52分，该股涨幅收窄至15%，报230.2港元，成交额超1.75亿港元。国泰海通证券近期发布研报，给予映恩生物-B\"增持\"评级，目标价300.70港元。此外，映恩生物产品管线丰富，ADC布局持续扩容，预计2025-2027年收入将稳步增长。券商的积极评级进一步提振了投资者信心，推动股价创下新高。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09606"],"gpt_icon":0},{"id":"2529318988","title":"港股異動 | 映恩生物-B(09606)漲超16%創新高 公司聚焦ADC新藥研發 核心產品初步展現治療潛力","url":"https://stock-news.laohu8.com/highlight/detail?id=2529318988","media":"智通财经网","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529318988?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 11:58","pubTimestamp":1745294280,"startTime":"0","endTime":"0","summary":"映恩生物-B午前涨超16%，高见232.8港元，创上市新高。截至发稿，涨13.2%，报226.4港元，成交额1.75亿港元。公开资料显示，映恩生物是全球抗体偶联药物领域的关键领跑者，致力于为癌症和自身免疫性疾病等患者研发ADC创新药物。公司拥有自主研发的两款核心产品，此外，公司有五项处于临床阶段的资产已获得美国食品药品管理局及中国国家药品监督管理局的研究用新药批准。国泰海通发布研报称，公司聚焦ADC新药研发，产品达成多项License-out对外授权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-22/doc-inetzepc5545457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09606","BK4231","ADC","BK4080"],"gpt_icon":1},{"id":"2529844691","title":"國泰海通：首予映恩生物-B(09606)“增持”評級 目標價300.70港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529844691","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529844691?lang=zh_tw&edition=fundamental","pubTime":"2025-04-21 14:25","pubTimestamp":1745216757,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国泰海通发布研报称，首次覆盖映恩生物-B，给予“增持”评级。预计2025-2027年收入16.00/19.76/22.07亿元，综合绝对估值法及相对估值法，给予目标价300.70港元/股。国泰海通主要观点如下：DB-1303：对标Enhertu更优，全球领先跟进。HER2ADC已成为HER2+BC等领域的重要治疗手段，Enhertu在临床持续取得突破，正在引领临床用药迭代。风险调整后预计国内峰值有望达26亿元、美国峰值有望达16亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1281412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09606"],"gpt_icon":1},{"id":"2529784214","title":"港股IPO週報：映恩生物-B首日暴漲116.7%，“最賺錢”卡牌龍頭卡遊等9家遞表","url":"https://stock-news.laohu8.com/highlight/detail?id=2529784214","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529784214?lang=zh_tw&edition=fundamental","pubTime":"2025-04-21 14:11","pubTimestamp":1745215867,"startTime":"0","endTime":"0","summary":"2025年以来，港股已有19只新股上市（包括1只转板，1只De-SPAC），合计募资约212.8亿港元。最近一周 （4月13日~4月19日），2家上市，0家招股，1家聆讯，9家递表。","market":"other","thumbnail":"https://images.finet.hk/photoLib/title/202504_1/8e797f06-d337-4216-8d64-b530081ea5e3.jpg","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202504_1/8e797f06-d337-4216-8d64-b530081ea5e3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/6805e17b23082936cbad6168","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["YANG","BK4614","09606","HSTECH"],"gpt_icon":1},{"id":"2527253432","title":"映恩生物上市暴漲116%，未來價值釋放值得期待","url":"https://stock-news.laohu8.com/highlight/detail?id=2527253432","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527253432?lang=zh_tw&edition=fundamental","pubTime":"2025-04-16 13:30","pubTimestamp":1744781436,"startTime":"0","endTime":"0","summary":"美国总统特朗普“对等关税”闹剧引发全球金融市场巨震，其还威胁将对药品征收关税，然而港股生物医药板块无惧威胁，表现可圈可点，凸显其韧性。","market":"other","thumbnail":"https://images.finet.hk/photoLib/title/202504_1/2ee4597b-d237-4ca0-ad81-8f699b0ff740.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202504_1/2ee4597b-d237-4ca0-ad81-8f699b0ff740.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/67ff407c2308299789d6828c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["09606"],"gpt_icon":1},{"id":"2527534280","title":"創下2022年以來18A融資規模新紀錄，ADC獨角獸映恩生物-B(09606)強勢登陸港股","url":"https://stock-news.laohu8.com/highlight/detail?id=2527534280","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527534280?lang=zh_tw&edition=fundamental","pubTime":"2025-04-16 12:09","pubTimestamp":1744776596,"startTime":"0","endTime":"0","summary":"坐拥自2022年以来18A生物科技板块内最大融资规模，暂居2025年港股IPO首日涨幅榜榜首......映恩生物-B凭借上述成绩，完成了从“国内ADC黑马”向“港股18A明星标的”的华丽转身。自2023年以来，映恩生物先后与BioNTech、百济神州、Adcendo、GSK、Avenzo、三生制药等国内外顶尖药企达成多项BD交易，总价值超60亿美元，助力公司成为国产ADC独角兽与出海“生力军”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1279367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4231","YANG","BK4080","BK4614","09606","ADC","HSTECH"],"gpt_icon":1},{"id":"2527402786","title":"映恩生物－Ｂ(09606)股價下跌5.366%，現價港幣$194.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2527402786","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527402786?lang=zh_tw&edition=fundamental","pubTime":"2025-04-16 09:40","pubTimestamp":1744767600,"startTime":"0","endTime":"0","summary":"[下跌股]映恩生物－Ｂ(09606) 股价在上午09:40比前收市价下跌5.366%，现股价为港币$194.0。至目前为止，今日最高价为$204.6，而最低价为$194.0。总成交量为17.98万股，总成交金额为港币$3.567千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD250416527/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09606"],"gpt_icon":0},{"id":"2527477255","title":"映恩生物登陸港交所首日大漲116.70%；百利天恆第10款ADC獲批臨牀試驗 | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2527477255","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527477255?lang=zh_tw&edition=fundamental","pubTime":"2025-04-16 07:40","pubTimestamp":1744760413,"startTime":"0","endTime":"0","summary":"NO.1映恩生物登陆港交所首日大涨116.70%4月15日，映恩生物正式在港交所挂牌，截至收盘股价大涨116.70%。公司本次IPO（首次公开发行）认购募资总额为2.1亿美元，约合人民币15.4亿元，刷新了2022年以来港股18A生物科技公司的融资纪录。资料显示，映恩生物成立于2019年，主要研发创新抗体偶联药物（ADC），用于治疗癌症、自身免疫性疾病等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504163377896945.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504163377896945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09606","BK1515","BK4080","BK1161","03347","BK1141","09939","BK1574","ADC","BK1583","BK4231","BK1576"],"gpt_icon":1},{"id":"2527104864","title":"映恩生物上市刷新港股18A多項紀錄 首日股價飆升超116%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527104864","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527104864?lang=zh_tw&edition=fundamental","pubTime":"2025-04-15 21:54","pubTimestamp":1744725256,"startTime":"0","endTime":"0","summary":"4月15日，抗体偶联药物（ADC）明星企业映恩生物正式在港交所挂牌上市，上市首日开盘价为181港元/股，高开91.3%，并快速拉涨突破200港元/股，截至收盘股价上涨至205港元/股，涨幅达116.7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504153377648929.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504153377648929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["YANG","09606","BK4614","HSTECH"],"gpt_icon":1},{"id":"2527419593","title":"映恩生物港股上市首日收漲116.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527419593","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527419593?lang=zh_tw&edition=fundamental","pubTime":"2025-04-15 20:57","pubTimestamp":1744721869,"startTime":"0","endTime":"0","summary":"北京商报讯（记者丁宁）4月15日，映恩生物（09606.HK）登录港交所，上市首日收涨116.7%，收盘价为205港元/股，总市值为175.1亿港元。招股书显示，映恩生物是一家专注于抗体偶联药物（ADC）研发的全球领跑企业，聚焦癌症及自身免疫性疾病领域。公司依托自主研发的四大技术平台，构建了差异化显著的创新管线，涵盖12款自主研发的ADC候选药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504153377602771.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504153377602771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4614","09606","HSTECH","YANG"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":67,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09606\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09606\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09606\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09606\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09606","date":"2025-04-30","current":-15.806523,"percent":0.6,"low":-17.183112,"twenty":-16.756996,"median":-15.846935,"eighty":-14.905978,"high":-7.368305,"avg":-15.17124,"sd":2.625448,"marketCap":17719522633},"quantilePoints":[{"date":"2025-04-17","current":-14.905978,"twenty":-15.065639,"median":-14.442293,"eighty":-11.334487,"marketCap":16635152800},{"date":"2025-04-25","current":-15.846935,"twenty":-16.770434,"median":-15.576033,"eighty":-14.349556,"marketCap":17719522633},{"date":"2025-04-30","current":-15.806523,"twenty":-16.756996,"median":-15.846935,"eighty":-14.905978,"marketCap":17719522633}],"updateTime":1746091967244}}}